HB1791 (2018) Detail

(New Title ) allowing pharmacists to disclose information relative to lower cost drugs under the managed care law and relative to biological products dispensed by pharmacists.


CHAPTER 164

HB 1791-FN - FINAL VERSION

 

05/03/2018   1637s

05/03/2018   1875s

 

2018 SESSION

18-2685

01/10

 

HOUSE BILL 1791-FN

 

AN ACT allowing pharmacists to disclose information relative to lower cost drugs under the managed care law and relative to biological products dispensed by pharmacists.

 

SPONSORS: Rep. Butler, Carr. 7; Rep. Rosenwald, Hills. 30; Rep. Williams, Hills. 4; Rep. Fothergill, Coos 1; Rep. Knirk, Carr. 3

 

COMMITTEE: Commerce and Consumer Affairs

 

-----------------------------------------------------------------

 

AMENDED ANALYSIS

 

This bill declares that a contract between an insurance carrier or pharmacy benefit manager and a contracted pharmacy shall not contain a provision prohibiting the pharmacist from providing certain information to an insured or the insurance department.

 

This bill also establishes requirements for dispensing and substituting biological products by pharmacists and establishes an annual education program relative to biological products.

 

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

 

Explanation: Matter added to current law appears in bold italics.

Matter removed from current law appears [in brackets and struckthrough.]

Matter which is either (a) all new or (b) repealed and reenacted appears in regular type.

05/03/2018   1637s

05/03/2018   1875s 18-2685

01/10

 

STATE OF NEW HAMPSHIRE

 

In the Year of Our Lord Two Thousand Eighteen

 

AN ACT allowing pharmacists to disclose information relative to lower cost drugs under the managed care law and relative to biological products dispensed by pharmacists.

 

Be it Enacted by the Senate and House of Representatives in General Court convened:

 

164:1  New Paragraph; Managed Care Law; Provider Contract Standards.  Amend RSA 420-J:8 by inserting after paragraph XV the following new paragraph:

XVI.  No contract between an insurance carrier or pharmacy benefit manager and a contracted pharmacy shall contain a provision prohibiting divulgence to a covered person or the insurance department relative to monetary matters which would prove beneficial in lowering costs to such covered person.

164:2  Prescription Labels.  Amend RSA 318:47-a to read as follows:

318:47-a  Prescription Labels.  Whenever a pharmacist dispenses a noncontrolled drug pursuant to a prescription, he or she shall affix to the container in which such drug is dispensed a label showing at least the name and address of the pharmacy and the name or initials of the dispensing pharmacist or pharmacist-in-charge; the prescription identification number assigned by the pharmacy; the date dispensed; any directions as may be stated on the prescription; the name of the prescribing practitioner; the name of the patient; all pertinent auxiliary labels; and, unless otherwise indicated by the prescribing physician, dentist, veterinarian, or advanced practice registered nurse, the name, strength, and quantity of the drug dispensed.  All drugs dispensed to a patient that have been filled using a centralized prescription processing system shall bear a label containing an identifiable code that provides a complete audit trail of the dispensing of the drug and pharmaceutical care activities.  A biological product, as defined in RSA 318:47-dd, I, shall also be labeled as provided in RSA 318:47-dd, VII.  No person shall alter, deface, or remove any label so affixed.  A compounded drug product shall also be labeled as provided in RSA 318:14-a, II.  The compound drug product shall bear the label of the pharmacy responsible for compounding and dispensing the product directly to the patient for administration, and the prescription shall be filed at that pharmacy.  Compounded prescription labels shall include the phrase "compounded per subscriber request'' or a similar statement on the prescription label or through the use of an auxiliary label attached to the prescription container.

164:3  Substituting Generic Drugs.  Amend RSA 318:47-d to read as follows:

318:47-d  Pharmacies; Substituting Generic Drugs.  Pharmacies, including mail-order pharmacies, may substitute generically equivalent drug products for all legend and non-legend prescriptions unless the prescribing practitioner handwrites "medically necessary'' on each paper prescription, or uses electronic indications when transmitted electronically, or gives instructions when transmitted orally that the brand name drug product is medically necessary.  In this section, "drug product" does not include a biological product.

164:4  New Section; Substituting Biological Products.  Amend RSA 318 by inserting after section 47-d the following new section:

318:47-dd  Pharmacies; Substituting Biological Products.

I.  In this section:

(a)  "Biological product" means a virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood component or derivative, allergenic product, protein (except any chemically synthesized polypeptide), or analogous product, or arsphenamine or derivative of arsphenamine (or any other trivalent organic arsenic compound), applicable to the prevention, treatment, or cure of a disease or condition of human beings.

(b)  "Proper name" means the nonproprietary name for a biological product designated by the federal Food and Drug Administration license for use upon each package of the product.

(c)  "Interchangeable biological product" means a biological product that the federal Food and Drug Administration:

(1)  Has licensed and determined meets the standards for interchangeability pursuant to 42 U.S.C. section 262(k)(4); or

(2)  Has determined is therapeutically equivalent as set forth in the latest edition of or supplement to the federal Food and Drug Administration's Approved Drug Products with Therapeutic Equivalence Evaluations.

II.  The board shall maintain a link on its website to the federal Food and Drug Administration's Lists of Licensed Biological Products with Reference Product Exclusivity and Biosimilarity or Interchangeability Evaluations.

III.  A pharmacist may substitute a biological product pursuant to this section only if it has been licensed by the federal Food and Drug Administration as an interchangeable biological product for the prescribed biological product.

IV.  When a pharmacist dispenses an interchangeable biological product for the prescribed biological product, the pharmacist or his or her designee shall inform the patient.

V.  A pharmacist shall not substitute an interchangeable biological product pursuant to this section if the prescriber indicates that substitution is not authorized by specifying on the prescription "medically necessary" on a paper prescription, or uses electronic indications when transmitted electronically, or gives instructions when transmitted orally that the biological product prescribed is medically necessary.

VI.(a)  Within 3 business days following the dispensing of a biological product, the dispensing pharmacist or the pharmacist's designee shall make an entry of the specific product provided to the patient, including the name of the product and the manufacturer.  The communication shall be conveyed by making an entry that is electronically accessible to the prescriber through:

(1)  An interoperable electronic medical records system;

(2)  An electronic prescribing technology; or

(3)  A pharmacy benefit management system; or

(4)  A pharmacy record.

(b)  Entry into an electronic records system as described in this paragraph is presumed to provide notice to the prescriber.  Otherwise, the pharmacist shall communicate the biological product dispensed to the prescriber using facsimile, telephone, electronic transmission, or other prevailing means, provided that the communication shall not be required where:

(1)  There is no federal Food and Drug Administration-approved interchangeable biological product for the biological product prescribed; or

(2)  A refill prescription is not changed from product dispensed on the prior filling of the prescription.

VII.  The label of all biological products dispensed by a pharmacist shall include the proper name and the name of the manufacturer of the product.

164:5  New Section; Physicians and Surgeons; Annual Education Program.  Amend RSA 329 by inserting after section 9-f the following new section:

329:9-g  Annual Education Program.  The board, in conjunction with the New Hampshire Medical Society and other prescribing and dispensing stakeholders, shall establish an annual education program that covers the prescribing of biosimilar and interchangeable biological products.  Such program shall include a review of interchangeable biological products approved by the federal Food and Drug Administration (FDA) including any evaluation information in determining interchangeability.  The annual education program shall be implemented by December 31, 2018 or prior to the first interchangeable biological product being approved by the FDA.

164:6  Effective Date.

I.  Section 5 of this act shall take effect upon its passage.

II.  The remainder of this act shall take effect January 1, 2019

 

Approved: June 07, 2018

Effective Date:

I. Section 5 shall take effect June 7, 2018

II. Remainder shall take effect January 1, 2019

 

 

Links

HB1791 at GenCourtMobile

Action Dates

Date Body Type
Jan. 17, 2018 House Hearing
Jan. 31, 2018 House Exec Session
House Floor Vote
Feb. 22, 2018 House Floor Vote
March 20, 2018 Senate Hearing
April 26, 2018 Senate Floor Vote
April 26, 2018 Senate Floor Vote
May 2, 2018 Senate Floor Vote
May 2, 2018 Senate Floor Vote
May 3, 2018 Senate Floor Vote

Bill Text Revisions

HB1791 Revision: 4118 Date: June 11, 2018, 10:54 a.m.
HB1791 Revision: 3849 Date: May 11, 2018, 9:27 a.m.
HB1791 Revision: 3767 Date: May 4, 2018, 3:12 p.m.
HB1791 Revision: 3758 Date: May 4, 2018, 1:31 p.m.
HB1791 Revision: 2383 Date: Dec. 5, 2017, 4:26 p.m.

Docket

Date Status
Jan. 3, 2018 Introduced 01/03/2018 and referred to Commerce and Consumer Affairs HJ 1 P. 23
Jan. 17, 2018 Public Hearing: 01/17/2018 10:30 AM LOB 302
Jan. 30, 2018 Subcommittee Work Session: 01/30/2018 11:15 AM LOB 302
Jan. 31, 2018 Executive Session: 01/31/2018 LOB 302
Feb. 22, 2018 Committee Report: Ought to Pass for 02/22/2018 (Vote 20-0; CC) HC 7 P. 5
Committee Report: Ought to Pass (Vote 20-0; CC)
Feb. 22, 2018 Ought to Pass: MA VV 02/22/2018 HJ 5 P. 5
March 8, 2018 Introduced 03/08/2018 and Referred to Health and Human Services; SJ 7
March 20, 2018 Hearing: 03/20/2018, Room 101, LOB, 01:30 pm; SC 13
April 26, 2018 Committee Report: Ought to Pass with Amendment # 2018-1637s, 04/26/2018; Vote 5-0; CC; SC 18
April 26, 2018 Sen. Bradley Moved to Remove HB 1791-FN from the Consent Calendar; 04/26/2018; SJ 14
May 2, 2018 Special Order to 05/02/2018, Without Objection, MA; 04/26/2018 SJ 14
May 2, 2018 Committee Report: Ought to Pass with Amendment # 2018-1637s, 05/02/2018; SC 19
May 3, 2018 Special Order to 05/03/2018, Without Objection, MA; 05/02/2018 SJ 15
May 3, 2018 Committee Report: Ought to Pass with Amendment # 2018-1637s, 05/03/2018;
May 3, 2018 Committee Amendment # 2018-1637s, AA, VV; 05/03/2018; SJ 16
May 3, 2018 Sen. Bradley Floor Amendment # 2018-1875s, RC 24Y-0N, AA; 05/03/2018; SJ 16
May 3, 2018 Ought to Pass with Amendments 2018-1637s and 2018-1875s, MA, VV; OT3rdg; 05/03/2018; SJ 16
May 10, 2018 House Concurs with Senate Amendment 1637s and 1875s (Rep. Hunt): MA VV 05/10/2018
May 10, 2018 Reconsider concurrence with amendments 1637s and 1875s (Rep. Knirk): MF VV 05/10/2018
May 23, 2018 Enrolled (In recess 05/23/2018); SJ 18
May 23, 2018 Enrolled 05/23/2018
June 7, 2018 Signed by Governor Sununu 06/07/2018; Chapter 164; I. Sec. 5 eff. 6/7/2018; II. Rem. eff. 1/1/2019